Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors

被引:33
作者
Canales, MA
Arrieta, R
Gomez-Rioja, R
Diez, J
Jimenez-Yuste, V
Hernandez-Navarro, F
机构
[1] Hosp Univ La Paz, Dept Hematol, Serv Hematol, Madrid 28046, Spain
[2] Hosp Univ La Paz, Invest Unit, Madrid 28046, Spain
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2002年 / 11卷 / 04期
关键词
D O I
10.1089/15258160260194820
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In June, 1997, we initiated a prospective study to analyze the effect of granulocyte colony-stimulating factor (G-CSF) on coagulation system in peripheral blood stem cells (PBSC) donors following G-CSF administration. Since, 25 consecutively healthy donors received G-CSF (filgrastim) to mobilize and collect PBSC and 20 donors were finally included in the study. Blood samples were collected immediately before starting G-CSF and prior to PBSC collection to analyze the following parameters: prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, hypercoagulability markers (D-dimer, TAT complex, F1 + 2), natural anticoagulants (antithrombin, protein C, protein S), endothelial activation markers [von Willebrand factor antigen (vWF:Ag) and angiotensin converting enzyme (ACE)], and resistance to activated protein C. We found a significant increase in F1 + 2 and D-dimer while a significant decrease of antithrombin and protein C activity was evidenced. Regarding endothelial cell activation markers, a significant increase of vWF:Ag with a slightly significant decrease of ACE were also observed. Therefore, in PBSC donors receiving G-CSF our results reveal activation of both coagulation and endothelial cells that could favor the developing of thrombotic events. In consequence, a careful monitoring should be considered in those cases with risk factors for thrombosis.
引用
收藏
页码:675 / 681
页数:7
相关论文
共 33 条
[1]   Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor [J].
Adkins, DR .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :812-813
[2]  
Altieri D C, 1995, Curr Opin Hematol, V2, P41
[3]  
ALTIERI DC, 1993, BLOOD, V81, P569
[4]  
Anderlini P, 1997, BLOOD, V90, P903
[5]   The use of mobilized peripheral blood stem cells from normal donors for allografting [J].
Anderlini, P ;
Korbling, M .
STEM CELLS, 1997, 15 (01) :9-17
[6]   Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures [J].
Anderlini, P ;
Przepiorka, D ;
Seong, D ;
Miller, P ;
Sundberg, J ;
Lichtiger, B ;
Norfleet, F ;
Chan, KW ;
Champlin, R ;
Korbling, M .
TRANSFUSION, 1996, 36 (07) :590-595
[7]   Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim:: the M.D. Anderson Cancer Center experience [J].
Anderlini, P ;
Donato, M ;
Chan, KW ;
Huh, YO ;
Gee, AP ;
Lauppe, MJ ;
Champlin, RE ;
Körbling, M .
TRANSFUSION, 1999, 39 (06) :555-560
[8]   EFFECT OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (RHG-CSF) ON CIRCULATING PLATELETS [J].
AVENARIUS, HJ ;
FREUND, M ;
DEINHARDT, J ;
POLIWODA, H .
ANNALS OF HEMATOLOGY, 1992, 65 (01) :6-9
[9]  
Becker P S, 1997, Biol Blood Marrow Transplant, V3, P45
[10]   ANGIOTENSIN-CONVERTING ENZYME - CLINICAL-APPLICATIONS AND LABORATORY INVESTIGATIONS ON SERUM AND OTHER BIOLOGICAL-FLUIDS [J].
BENETEAUBURNAT, B ;
BAUDIN, B .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1991, 28 (5-6) :337-356